Stephen P. Macmillan - Nov 29, 2023 Form 4 Insider Report for HOLOGIC INC (HOLX)

Role: Chairman, President and CEO, Director
Signature: /s/ Mark W. Irving, attorney-in-fact for Mr. MacMillan
Stock symbol: HOLX
Transactions as of: Nov 29, 2023
Transactions value $: -$2,108,683
Form type: 4
Date filed: 12/1/2023, 04:04 PM
Previous filing: Nov 16, 2023
Next filing: Apr 23, 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	HOLX	Common Stock	Options Exercise	$1.25M	+47.7K	+3.85%	$26.21	1.29M	Nov 29, 2023	Direct	F1, F2
transaction	HOLX	Common Stock	Sale	-$3.36M	-47.7K	-3.71%	$70.41	1.24M	Nov 29, 2023	Direct	F1, F2, F3
holding	HOLX	Common Stock						1.06M	Nov 29, 2023	MacMillan Family Trust

Showing 1 to 3 of 3 entries

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	HOLX	Non-qualified Stock Option (Right to Buy)	Options Exercise	$0	-47.7K	-50%	$0.00	47.7K	Nov 29, 2023	Common Stock	47.7K	$26.21	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id	Content
F1	Transaction pursuant to an existing Rule 10b5-1 trading plan adopted August 30, 2023 to exercise and sell expiring stock options.
F2	Includes 1,079,673 restricted stock units/performance stock units, the settlement of which has been deferred pursuant to the Issuer's Deferred Equity Plan.
F3	The price reported is the weighted average price per share. Shares were sold in multiple transactions at prices ranging from $69.95 to $70.85 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each price.
F4	This option to purchase common stock became exercisable in equal installments on each of the first five anniversaries of the grant date, November 7, 2014.